Inhibikase Therapeutics (IKT) Assets Average (2021 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Assets Average of $177.3 million for Q1 2026, up 83.81% year-over-year from $96.4 million in Q1 2025, and up 35.94% quarter-over-quarter from $130.4 million in Q4 2025.
Inhibikase Therapeutics (IKT) Assets Average (2021 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Assets Average for 6 consecutive years, with $177.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 83.81% year-over-year to $177.3 million; the TTM figure through Mar 2026 stood at $177.3 million (up 83.81% YoY), while the FY2025 annual figure was $139.9 million, up 147.38% from the prior year.
- Assets Average climbed to $177.3 million in Q1 2026 per IKT's latest filing, from $130.4 million in the prior quarter.
- Across five years, Assets Average topped out at $177.3 million in Q1 2026 and bottomed at $6.6 million in Q3 2024.
- Historically, Assets Average has averaged $52.0 million across 5 years, with a median of $31.3 million in 2022.
- Annual changes were most pronounced in 2024 — Assets Average tumbled 67.18% — and 2025, when it jumped 1175.76%.
- Inhibikase Therapeutics' Assets Average stood at $26.8 million in 2022, then plunged by 39.48% to $16.2 million in 2023, then soared by 217.95% to $51.5 million in 2024, then surged by 153.26% to $130.4 million in 2025, then surged by 35.94% to $177.3 million in 2026.
- Business Quant data shows IKT's Assets Average at $177.3 million in Q1 2026, $130.4 million in Q4 2025, and $84.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 168.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 168.46 Mn |
| Mar 31, 2026 | 177.27 Mn |
| Dec 31, 2025 | 130.40 Mn |
| Sep 30, 2025 | 84.22 Mn |
| Jun 30, 2025 | 91.57 Mn |
| Mar 31, 2025 | 96.44 Mn |
| Dec 31, 2024 | 51.49 Mn |
| Sep 30, 2024 | 6.60 Mn |
| Jun 30, 2024 | 9.95 Mn |
| Mar 31, 2024 | 12.79 Mn |
| Dec 31, 2023 | 16.19 Mn |
| Sep 30, 2023 | 20.11 Mn |
| Jun 30, 2023 | 25.26 Mn |
| Mar 31, 2023 | 26.55 Mn |
| Dec 31, 2022 | 26.76 Mn |
| Sep 30, 2022 | 31.29 Mn |
| Jun 30, 2022 | 36.19 Mn |
| Mar 31, 2022 | 40.43 Mn |
| Dec 31, 2021 | 44.17 Mn |
| Sep 30, 2021 | 47.54 Mn |